Merck & Co., Inc. $MRK Stock Purchased by Signaturefd LLC

Signaturefd LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 7.4% in the third quarter, Holdings Channel reports. The fund owned 61,332 shares of the company’s stock after buying an additional 4,208 shares during the period. Signaturefd LLC’s holdings in Merck & Co., Inc. were worth $8,912,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Bullseye Investment Management LLC purchased a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $27,000. Curry Webb Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at $29,000. Horizons Wealth Management purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth $30,000. Graney & King LLC lifted its position in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth $41,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $145.25 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92. The firm’s 50 day moving average is $146.98 and its two-hundred day moving average is $130.17. The firm has a market capitalization of $358.35 billion, a P/E ratio of 116.20, a P/E/G ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts forecast that Merck & Co., Inc. will post 2.64 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Insider Activity

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last three months. Company insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, October 5th. Argus lifted their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Royal Bank Of Canada decreased their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a report on Monday, October 12th. Sanford C. Bernstein upped their price objective on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley lowered their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Seventeen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.